First-line immunotherapy for advanced non-small cell lung cancer: current progress and future prospects.
作者信息
Wang Jingyi, Wu Lin
机构信息
The Second Department of Thoracic Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.
Xiangya Lung Cancer Center, Xiangya Hospital, Central South University, Changsha 410008, China.
出版信息
Cancer Biol Med. 2023 Dec 26;21(2):117-24. doi: 10.20892/j.issn.2095-3941.2023.0401.
Abstract
摘要
相似文献
1
First-line immunotherapy for advanced non-small cell lung cancer: current progress and future prospects.晚期非小细胞肺癌的一线免疫治疗：当前进展与未来展望
Cancer Biol Med. 2023 Dec 26;21(2):117-24. doi: 10.20892/j.issn.2095-3941.2023.0401.
2
Immunotherapy for non-small cell lung cancer.非小细胞肺癌的免疫疗法
JAAPA. 2019 Sep;32(9):37-42. doi: 10.1097/01.JAA.0000569792.99069.e6.
3
Lung cancer in 2016: immunotherapy comes of age.2016年的肺癌：免疫疗法走向成熟。
Lancet Respir Med. 2016 Dec;4(12):947-949. doi: 10.1016/S2213-2600(16)30379-4. Epub 2016 Nov 22.
4
Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer.免疫检查点抑制剂作为晚期非小细胞肺癌的一线及挽救治疗
Future Oncol. 2016 Aug;12(15):1805-22. doi: 10.2217/fon-2016-0086. Epub 2016 Jun 8.
5
Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?成功与失败：我们从近期非小细胞肺癌一线治疗免疫疗法试验中学到了什么？
BMC Med. 2017 Mar 13;15(1):55. doi: 10.1186/s12916-017-0819-3.
6
Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches.晚期非小细胞肺癌患者一线治疗中的免疫检查点抑制：现状与未来方法
Lung Cancer. 2017 Apr;106:70-75. doi: 10.1016/j.lungcan.2017.02.002. Epub 2017 Feb 6.
7
Immunotherapy: pembrolizumab-is the writing on the wall for cancer?免疫疗法：帕博利珠单抗——癌症的不祥之兆？
Nat Rev Clin Oncol. 2015 Jul;12(7):371. doi: 10.1038/nrclinonc.2015.85. Epub 2015 May 12.
8
First Anti-PD-L1 Drug Approved for NSCLC.首个抗 PD-L1 药物获批用于 NSCLC。
Cancer Discov. 2016 Dec;6(12):OF1. doi: 10.1158/2159-8290.CD-NB2016-143. Epub 2016 Nov 14.
9
[A Reflection of the New Wave of Immunotherapy on the Clinical Study of
Chinese Lung Cancer Immunotherapy].[免疫治疗新浪潮对中国肺癌免疫治疗临床研究的思考]
Zhongguo Fei Ai Za Zhi. 2017 Oct 20;20(10):695-702. doi: 10.3779/j.issn.1009-3419.2017.10.06.
10
[A Case of Pseudoprogression During Atezolizumab Therapy
in Lung Adenocarcinoma].[1例肺腺癌阿替利珠单抗治疗期间假性进展的病例]
Zhongguo Fei Ai Za Zhi. 2019 Jun 20;22(6):389-394. doi: 10.3779/j.issn.1009-3419.2019.06.10.
引用本文的文献
1
The prognostic significance and Immunomodulatory role of SCGB3A1 expression in stage I lung adenocarcinoma.SCGB3A1表达在I期肺腺癌中的预后意义及免疫调节作用
BMC Med Genomics. 2025 Jul 21;18(1):119. doi: 10.1186/s12920-025-02192-7.
2
Sd-021, derivatives of decursin, inhibits tumorigenesis in NSCLC by inhibiting the EGFR/STAT3 signaling pathway.Sd-021，去甲氧基莪术二酮衍生物，通过抑制EGFR/STAT3信号通路抑制非小细胞肺癌的肿瘤发生。
Sci Rep. 2025 Jul 2;15(1):22881. doi: 10.1038/s41598-025-05715-5.
3
Machine learning-guided single-cell multiomics uncovers GDF15-driven immunosuppressive niches in NSCLC: A translational framework for overcoming anti-PD-1 resistance.机器学习引导的单细胞多组学揭示非小细胞肺癌中GDF15驱动的免疫抑制微环境：克服抗PD-1耐药性的转化框架
Transl Oncol. 2025 Jun 28;59:102459. doi: 10.1016/j.tranon.2025.102459.
4
Applications of mRNA Delivery in Cancer Immunotherapy.信使核糖核酸递送在癌症免疫治疗中的应用
Int J Nanomedicine. 2025 Mar 17;20:3339-3361. doi: 10.2147/IJN.S500520. eCollection 2025.
5
The Role of Stereotactic Body Radiotherapy in Oligometastatic Non-Small Cell Lung Cancer.立体定向体部放射治疗在寡转移非小细胞肺癌中的作用
Curr Oncol. 2024 Dec 15;31(12):7971-7978. doi: 10.3390/curroncol31120588.
本文引用的文献
1
Potential biomarkers for immunotherapy in non-small-cell lung cancer.非小细胞肺癌免疫治疗的潜在生物标志物。
Cancer Metastasis Rev. 2023 Sep;42(3):661-675. doi: 10.1007/s10555-022-10074-y. Epub 2023 May 1.
2
NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023.美国国立综合癌症网络（NCCN）指南见解：非小细胞肺癌，2023年第2版
J Natl Compr Canc Netw. 2023 Apr;21(4):340-350. doi: 10.6004/jnccn.2023.0020.
3
Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers.转移性非小细胞肺癌的免疫治疗：治疗进展和生物标志物。
Curr Oncol. 2023 Feb 16;30(2):2366-2387. doi: 10.3390/curroncol30020181.
4
Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study.帕博利珠单抗联合化疗治疗鳞状非小细胞肺癌：III 期 KEYNOTE-407 研究的 5 年更新结果。
J Clin Oncol. 2023 Apr 10;41(11):1999-2006. doi: 10.1200/JCO.22.01990. Epub 2023 Feb 3.
5
Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer.优化晚期非小细胞肺癌免疫治疗效果的当前及新型治疗策略
Front Oncol. 2022 Dec 8;12:962947. doi: 10.3389/fonc.2022.962947. eCollection 2022.
6
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.度伐利尤单抗联合或不联合替西木单抗联合化疗作为转移性非小细胞肺癌一线治疗的 III 期 POSEIDON 研究。
J Clin Oncol. 2023 Feb 20;41(6):1213-1227. doi: 10.1200/JCO.22.00975. Epub 2022 Nov 3.
7
Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01).特瑞普利单抗联合化疗用于未经治疗的晚期非小细胞肺癌患者的多中心随机 III 期临床试验（CHOICE-01）。
J Clin Oncol. 2023 Jan 20;41(3):651-663. doi: 10.1200/JCO.22.00727. Epub 2022 Oct 7.
8
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial.西妥昔单抗联合化疗对比单纯化疗治疗非小细胞肺癌：一项随机、对照、双盲的 3 期临床试验。
Nat Med. 2022 Nov;28(11):2374-2380. doi: 10.1038/s41591-022-01977-y. Epub 2022 Aug 25.
9
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects.免疫检查点抑制剂在非小细胞肺癌中的应用：进展、挑战与展望。
Cells. 2022 Jan 19;11(3):320. doi: 10.3390/cells11030320.
10
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial.舒格利单抗联合铂类化疗对比安慰剂一线治疗转移性非小细胞肺癌（GEMSTONE-302）：一项双盲、随机、III 期临床研究的期中及最终分析。
Lancet Oncol. 2022 Feb;23(2):220-233. doi: 10.1016/S1470-2045(21)00650-1. Epub 2022 Jan 14.
Zotero 插件